top of page
We improve the management of chronic diseases
thanks to standardized, clinical-grade gut microbiome analysis
bringing microbiomics to the clinic
Mental disorders
Diabetes
Liver diseases
Bowel diseases
Cancer
We leverage standardized analytical procedures, high-quality quantitative metagenomics and proprietary AI-based algorithms to bring robust and reproducible microbiome analysis to clinicians. Our microbiome analysis software is a CE-marked medical device for in vitro diagnostic offered through medical labs and hospitals.
GMT Science’s mission is to allow physicians to leverage the microbiome in their clinical practice, starting with immuno-oncology.
Robust, reliable and precise microbiome analysis
This offers opportunities to use microbiome-based biomarkers in clinical management.
However, clinicians are still in need of reliable solutions to assess the microbiome of their patients for disease prevention, monitoring and prognosis.
Mounting evidence points to changes in the composition and functionality of the gut microbiota in a growing list of medical conditions such as cancer, liver and bowel diseases, diabetes, obesity and mental disorders.
Microbiome science with clinical value
TECHNOLOGY
Francisco Guarner, MD, PhD
Fay Betsou, PhD
SCIENTIFIC ADVISORY BOARD
Baptiste Hennecart
Bioinformatics
Florian Plaza Oñate, PhD
Bioinformatics
Thomas Moncion, PhD
Software development
Vadim Puller, PhD
Bioinformatics
Michel Laborde, MD
Medical IT Adviser
Edi Prifti, PhD
Data Science & biostat adviser
Pierre Dechelotte, MD, PhD
Medical Adviser
Joël Doré, PhD
Microbiome Science Adviser
Thomas Joder
CBO
Benjamin Duplan
CFO
Raynald de Lahondès, PhD
CTO
Etienne Formstecher, PhD
CEO
TEAM
.png)
SUPPORT FROM
MEMBER OF
.png)
PARTNERSHIPS
INVESTORS
NEWS
LAB
75 route de Lyons-la-Forêt, 76000 Rouen
OFFICES
8 Rue Jean Antoine de Baïf, 75013 Paris
CONTACT
bottom of page